Cargando…

Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis

Previous work has demonstrated that the hormone prolactin promotes oligodendrocyte precursor proliferation and remyelination following lysolecithin-induced demyelination of the mouse spinal cord. Prolactin, however, can elicit pro-inflammatory responses, and its use in the prototypical demyelinating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhornitsky, Simon, Johnson, Trina A, Metz, Luanne M, Weiss, Samuel, Yong, V Wee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367923/ https://www.ncbi.nlm.nih.gov/pubmed/25889599 http://dx.doi.org/10.1186/s12974-015-0278-8

Ejemplares similares

1,25-Dihydroxyvitamin D(3) Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis
por: Sloka, Scott, et al.
Publicado: (2015)

Environmental factors and their regulation of immunity in multiple sclerosis
por: Koch, Marcus W., et al.
Publicado: (2013)

Focus on the gut-brain axis: Multiple sclerosis, the intestinal barrier and the microbiome
por: Camara-Lemarroy, Carlos R, et al.
Publicado: (2018)

Reduction of microglial activity in a model of multiple sclerosis by dipyridamole
por: Sloka, Scott, et al.
Publicado: (2013)

Expanding the Potential Therapeutic Options for Remote Ischemic Preconditioning: Use in Multiple Sclerosis
por: Camara-Lemarroy, Carlos R., et al.
Publicado: (2018)

Distinct characteristics and severity of brain magnetic resonance imaging lesions in women and men with multiple sclerosis assessed using verified texture analysis measures
por: Hosseinpour, Zahra, et al.
Publicado: (2023)

Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic
por: Faissner, Simon, et al.
Publicado: (2017)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

Oral contraceptives combined with interferon β in multiple sclerosis
por: Pozzilli, Carlo, et al.
Publicado: (2015)

Discriminative ability of quality of life measures in multiple sclerosis
por: Fiest, Kirsten M., et al.
Publicado: (2017)

Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study
por: Zhornitsky, Simon, et al.
Publicado: (2015)

Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2015)

Expression of risk genes linked to vitamin D receptor super-enhancer regions and their association with phenotype severity in multiple sclerosis
por: Orton, Sarah M., et al.
Publicado: (2022)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Early stage and long term treatment of multiple sclerosis with interferon-β
por: Applebee, Angela, et al.
Publicado: (2009)

Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis
por: Kolb-Mäurer, Annette, et al.
Publicado: (2015)

Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis
por: De Giglio, L., et al.
Publicado: (2015)

Interferon-β1a reduces plasma CD31+ endothelial microparticles (CD31+EMP) in multiple sclerosis
por: Sheremata, William A, et al.
Publicado: (2006)

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
por: Hegen, Harald, et al.
Publicado: (2016)

Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Advanced diffusion MRI and image texture analysis detect widespread brain structural differences between relapsing-remitting and secondary progressive multiple sclerosis
por: Oladosu, Olayinka, et al.
Publicado: (2022)

Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2019)

Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosis
por: Tayyab, Maryam, et al.
Publicado: (2023)

Advanced Analysis of Diffusion Tensor Imaging Along With Machine Learning Provides New Sensitive Measures of Tissue Pathology and Intra-Lesion Activity in Multiple Sclerosis
por: Oladosu, Olayinka, et al.
Publicado: (2021)

Review of the clinical evidence for interferon β 1a (Rebif(®)) in the treatment of multiple sclerosis
por: Manfredonia, Francesco, et al.
Publicado: (2008)

Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases
por: Etemadifar, Masoud, et al.
Publicado: (2011)

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Bone marrow sarcoidosis associated with long‐term interferon‐β treatment for multiple sclerosis
por: Teh, Angela, et al.
Publicado: (2016)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis
por: Bogie, Jeroen FJ, et al.
Publicado: (2020)

The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design
por: Oh, Jiwon, et al.
Publicado: (2021)

Novel Approaches to Detect Serum Biomarkers for Clinical Response to Interferon-β Treatment in Multiple Sclerosis
por: Gandhi, Kaushal S., et al.
Publicado: (2010)

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β
por: De Felice, Bruna, et al.
Publicado: (2014)

Delayed Liver Function Impairment Secondary to Interferon β-1a Use in Multiple Sclerosis
por: Liao, Ming-Feng, et al.
Publicado: (2013)

Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
por: Yetkin, Mehmet Fatih, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pdc6v7ec9buki7upqbnr1s65km